Coinfection
EASL 2013: HIV/HCV Coinfected at Risk for Decompensation, May Need Prompt Treatment
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIV positive people with hepatitis C coinfection may experience liver decompensation with advanced fibrosis, even before they progress to cirrhosis, and may therefore benefit from earlier antiviral treatment, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Tuesday, 12 March 2013 00:00
- Written by Liz Highleyman
Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
HIV+ People Who Acquire Hepatitis C May Have Impaired HCV-specific Interferon Response
- Details
- Category: HIV/HCV Coinfection
- Published on Friday, 26 October 2012 00:00
- Written by Liz Highleyman
People who already have HIV when they become infected with hepatitis C virus (HCV) appear to have reduced production of cytokines including natural interferons active against HCV, according to a study described in the November 15, 2012, Journal of Infectious Diseases.
CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Friday, 08 March 2013 00:00
- Written by Gregory Fowler
Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Hepatitis C Treatment Adherence Is Important for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 16 October 2012 00:00
- Written by Liz Highleyman
Near-perfect adherence to pegylated interferon plus ribavirin offers the best chance of sustained virological response -- or a cure -- for HIV positive people coinfected with hepatitis C virus (HCV), according to a U.S. veterans study described in the August 21, 2012, advance online edition of AIDS and Behavior.
Tenofovir plus Emtricitabine or Lamivudine Does Not Always Suppress Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HIV/HBV Coinfection
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people with high hepatitis B virus (HBV) levels and those who are HBeAg positive are at greater risk of not achieving HBV suppression after a year on tenofovir plus emtricitabine or lamivudine, but most did so eventually, researchers reported in the February 21, 2013, advance online edition of AIDS.
Tenofovir Leads to HBsAg Clearance in 8% of HIV/HBV Coinfected Patients
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 02 October 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) led to hepatitis B surface antigen (HBsAg) clearance -- considered the closest outcome to a cure -- in 8% of HIV positive patients with chronic hepatitis B virus (HBV) coinfection, and in a subgroup clearance was associated with CD4 T-cell count, Dutch researchers reported in the September 15, 2012, Journal of Infectious Diseases.
AASLD 2012: Final Study Results Show Telaprevir Is Safe and Effective for HIV/HCV Coinfected Patients
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
HIV/HCV coinfected people treated with telaprevir (Incivek) triple therapy are significantly more likely to achieve sustained virological response, or a cure, than people treated with pegylated interferon/ribavirin alone, according to final results from Study 110 presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.
ICAAC 2012: Raltegravir Shows Long-term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
The HIV integrase inhibitor raltegravir (Isentress) was well-tolerated and demonstrated continued effectiveness for 5 years in treatment-naive and 3 years in treatment-experienced HIV patients coinfected with hepatitis B or C, according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.
Web Design and Development by